Lin Jin, Gallagher Martin, Bellomo Rinaldo, Duan Meili, Trongtrakul Konlawi, Wang Amanda Ying
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Nephrology (Carlton). 2019 May;24(5):518-525. doi: 10.1111/nep.13387.
To evaluate the prognostic value of baseline SOFA coagulation score (SOFA-CS) and change in platelet counts in patients with severe acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT).
We performed a secondary analysis from the Randomized Evaluation of Normal versus Augmented Level of RRT (RENAL) study. The primary endpoint was all-cause mortality at 90 days after randomization. The association between baseline SOFA-CS, changes in platelet counts, process of care, and clinical outcomes were analyzed using multivariate Cox model adjusted for baseline variables.
The complete SOFA-CS data were available in 1454 out of 1508 patients from the RENAL study. Among them, 708 patients had an abnormal SOFA-CS (defined as SOFA-CS ≥ 1), while 746 patients had normal SOFA-CS at baseline (SOFA-CS = 0). An abnormal SOFA-CS was independently associated with an increased risk of death at 90 days (HR = 1.27, 95% CI = 1.05-1.53, P = 0.015). An abnormal SOFA-CS was associated with prolonged length of ICU stay and duration of mechanical ventilation as well. Furthermore, there was no significant association between changes in platelet counts in patients who survived beyond 4 days and 90 day mortality (HR = 1.26, 95% CI = 0.29-5.56, P = 0.76). However, on multivariable analysis a decline of ≥60% (HR = 1.93, 95% CI = 1.23-3.05, P = 0.004) was associated with 90 day mortality in patients who survived beyond the first 4 days.
In the RENAL study, thrombocytopaenia is a common phenomenon in patients with severe AKI receiving CRRT. An abnormal baseline SOFA-CS and reductions in platelet counts were associated with increased mortality at 90 days.
评估基线序贯器官衰竭评估凝血评分(SOFA-CS)及血小板计数变化对需要持续肾脏替代治疗(CRRT)的重症急性肾损伤(AKI)患者的预后价值。
我们对随机评估常规与强化水平肾脏替代治疗(RENAL)研究进行了二次分析。主要终点是随机分组后90天的全因死亡率。使用针对基线变量进行调整的多变量Cox模型分析基线SOFA-CS、血小板计数变化、治疗过程与临床结局之间的关联。
RENAL研究的1508例患者中,1454例有完整的SOFA-CS数据。其中,708例患者SOFA-CS异常(定义为SOFA-CS≥1),而746例患者基线时SOFA-CS正常(SOFA-CS = 0)。SOFA-CS异常与90天时死亡风险增加独立相关(HR = 1.27,95%CI = 1.05 - 1.53,P = 0.015)。SOFA-CS异常还与ICU住院时间延长及机械通气时间延长相关。此外,存活超过4天的患者血小板计数变化与90天死亡率之间无显著关联(HR = 1.26,95%CI = 0.29 - 5.56,P = 0.76)。然而,多变量分析显示,存活超过前4天的患者血小板计数下降≥60%与90天死亡率相关(HR = 1.93,95%CI = 1.23 - 3.05,P = 0.004)。
在RENAL研究中,血小板减少是接受CRRT的重症AKI患者中的常见现象。基线SOFA-CS异常及血小板计数降低与90天死亡率增加相关。